Cingulate (CING) Receivables (2023 - 2024)
Cingulate's (CING) quarterly Receivables came in at $2247.0 in Q3 2024, down 99.86% on a QoQ basis from $1.6 million in Q2 2024.
Cingulate (CING) Receivables (2023 - 2024) Analysis & Trends
Cingulate (CING) has 2 years of Receivables data on file, last reported at $2247.0 in Q3 2024.
- Quarterly Receivables changed N/A year-over-year to $2247.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $2247.0 (changed N/A YoY) and the FY2023 annual result came in at $14622.0, changed N/A from the prior year.
- Receivables slipped to $2247.0 in Q3 2024, from $1.6 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $1.6 million in Q2 2024 to a low of $2247.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cingulate | 72.85 Mn | 72.85 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 2,247.00 |
| Jun 30, 2024 | 1.62 Mn |
| Dec 31, 2023 | 14,622.00 |